VenoStent Technology Receives Breakthrough Device Designation by FDA tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
VenoStent Announces $2.3M in Seed Funding to Transform Vascular Access Surgery for Hemodialysis Patients
Share Article
Creative Ventures leads the funding round, with participation from IAG Capital Partners While we are laser-focused on our first indication, hemodialysis access, what’s additionally so exciting is that this approach avails to us a whole host of potential applications in ‘perivascular wrapping,’ said Geoff Lucks, VenoStent’s Co-Founder and COO. NASHVILLE, Tenn. (PRWEB) February 23, 2021
VenoStent, a Houston-based advanced materials company, today announced $2.3M in seed funding. The company leverages its unique polymer engineering technology to develop bioresorbable slip-on polymer wraps, called SelfWrap. The product is aimed to eliminate vascular surgery failures, at first targeting vascular access surgery required to initiate hemodialysis treatment for end-stage renal disease (ESRD) pat